Evolution of the Use of Corticosteroids for the Treatment of Hospitalised COVID-19 Patients in Spain between March and November 2020: SEMI-COVID National Registry

Objectives: Since the results of the RECOVERY trial, WHO recommendations about the use of corticosteroids (CTs) in COVID-19 have changed. The aim of the study is to analyse the evolutive use of CTs in Spain during the pandemic to assess the potential influence of new recommendations. Material and me...

Descripción completa

Detalles Bibliográficos
Autores: Balaz D, Wikman-Jorgensen PE, Galvañ VG, Rubio-Rivas M, de Miguel Campo B, López MN, Caleya JFL, Huelgas RG, Fontán PMP, Bailón MM, Fernández-Garcés M, Cruz AF, García GMG, Rhyman N, Corral-Gudino L, Rodríguez-Mancheño AL, De La Chica MN, García AT, Alcalá JN, Jiménez PD, Trallero LER, Casanova PC, Núñez-Cortés JM, Casas-Rojo JM, On Behalf Of The Semi-Covid-Network
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p11503
Acceso en línea:https://fisabio.portalinvestigacion.com/publicaciones/11503
Access Level:acceso abierto
Palabra clave:COVID-19
corticosteroids
Spain
comorbidities
id ES_f738c6e6395c1bab1a2da8a75fa256ed
oai_identifier_str oai:fisabio.fundanetsuite.com:p11503
network_acronym_str ES
network_name_str España
repository_id_str
spelling Evolution of the Use of Corticosteroids for the Treatment of Hospitalised COVID-19 Patients in Spain between March and November 2020: SEMI-COVID National RegistryBalaz DWikman-Jorgensen PEGalvañ VGRubio-Rivas Mde Miguel Campo BLópez MNCaleya JFLHuelgas RGFontán PMPBailón MMFernández-Garcés MCruz AFGarcía GMGRhyman NCorral-Gudino LRodríguez-Mancheño ALDe La Chica MNGarcía ATAlcalá JNJiménez PDTrallero LERCasanova PCNúñez-Cortés JMCasas-Rojo JMOn Behalf Of The Semi-Covid-NetworkCOVID-19corticosteroidsSpaincomorbiditiesObjectives: Since the results of the RECOVERY trial, WHO recommendations about the use of corticosteroids (CTs) in COVID-19 have changed. The aim of the study is to analyse the evolutive use of CTs in Spain during the pandemic to assess the potential influence of new recommendations. Material and methods: A retrospective, descriptive, and observational study was conducted on adults hospitalised due to COVID-19 in Spain who were included in the SEMI-COVID-19 Registry from March to November 2020. Results: CTs were used in 6053 (36.21%) of the included patients. The patients were older (mean (SD)) (69.6 (14.6) vs. 66.0 (16.8) years; p < 0.001), with hypertension (57.0% vs. 47.7%; p < 0.001), obesity (26.4% vs. 19.3%; p < 0.0001), and multimorbidity prevalence (20.6% vs. 16.1%; p < 0.001). These patients had higher values (mean (95% CI)) of C-reactive protein (CRP) (86 (32.7-160) vs. 49.3 (16-109) mg/dL; p < 0.001), ferritin (791 (393-1534) vs. 470 (236-996) mu g/dL; p < 0.001), D dimer (750 (430-1400) vs. 617 (345-1180) mu g/dL; p < 0.001), and lower Sp0(2)/Fi0(2) (266 (91.1) vs. 301 (101); p < 0.001). Since June 2020, there was an increment in the use of CTs (March vs. September; p < 0.001). Overall, 20% did not receive steroids, and 40% received less than 200 mg accumulated prednisone equivalent dose (APED). Severe patients are treated with higher doses. The mortality benefit was observed in patients with oxygen saturation </=90%. Conclusions: Patients with greater comorbidity, severity, and inflammatory markers were those treated with CTs. In severe patients, there is a trend towards the use of higher doses. The mortality benefit was observed in patients with oxygen saturation </=90%.MDPI2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/11503Journal of Clinical MedicineISSN: 20770383reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p115032026-06-11T12:45:17Z
dc.title.none.fl_str_mv Evolution of the Use of Corticosteroids for the Treatment of Hospitalised COVID-19 Patients in Spain between March and November 2020: SEMI-COVID National Registry
title Evolution of the Use of Corticosteroids for the Treatment of Hospitalised COVID-19 Patients in Spain between March and November 2020: SEMI-COVID National Registry
spellingShingle Evolution of the Use of Corticosteroids for the Treatment of Hospitalised COVID-19 Patients in Spain between March and November 2020: SEMI-COVID National Registry
Balaz D
COVID-19
corticosteroids
Spain
comorbidities
title_short Evolution of the Use of Corticosteroids for the Treatment of Hospitalised COVID-19 Patients in Spain between March and November 2020: SEMI-COVID National Registry
title_full Evolution of the Use of Corticosteroids for the Treatment of Hospitalised COVID-19 Patients in Spain between March and November 2020: SEMI-COVID National Registry
title_fullStr Evolution of the Use of Corticosteroids for the Treatment of Hospitalised COVID-19 Patients in Spain between March and November 2020: SEMI-COVID National Registry
title_full_unstemmed Evolution of the Use of Corticosteroids for the Treatment of Hospitalised COVID-19 Patients in Spain between March and November 2020: SEMI-COVID National Registry
title_sort Evolution of the Use of Corticosteroids for the Treatment of Hospitalised COVID-19 Patients in Spain between March and November 2020: SEMI-COVID National Registry
dc.creator.none.fl_str_mv Balaz D
Wikman-Jorgensen PE
Galvañ VG
Rubio-Rivas M
de Miguel Campo B
López MN
Caleya JFL
Huelgas RG
Fontán PMP
Bailón MM
Fernández-Garcés M
Cruz AF
García GMG
Rhyman N
Corral-Gudino L
Rodríguez-Mancheño AL
De La Chica MN
García AT
Alcalá JN
Jiménez PD
Trallero LER
Casanova PC
Núñez-Cortés JM
Casas-Rojo JM
On Behalf Of The Semi-Covid-Network
author Balaz D
author_facet Balaz D
Wikman-Jorgensen PE
Galvañ VG
Rubio-Rivas M
de Miguel Campo B
López MN
Caleya JFL
Huelgas RG
Fontán PMP
Bailón MM
Fernández-Garcés M
Cruz AF
García GMG
Rhyman N
Corral-Gudino L
Rodríguez-Mancheño AL
De La Chica MN
García AT
Alcalá JN
Jiménez PD
Trallero LER
Casanova PC
Núñez-Cortés JM
Casas-Rojo JM
On Behalf Of The Semi-Covid-Network
author_role author
author2 Wikman-Jorgensen PE
Galvañ VG
Rubio-Rivas M
de Miguel Campo B
López MN
Caleya JFL
Huelgas RG
Fontán PMP
Bailón MM
Fernández-Garcés M
Cruz AF
García GMG
Rhyman N
Corral-Gudino L
Rodríguez-Mancheño AL
De La Chica MN
García AT
Alcalá JN
Jiménez PD
Trallero LER
Casanova PC
Núñez-Cortés JM
Casas-Rojo JM
On Behalf Of The Semi-Covid-Network
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv COVID-19
corticosteroids
Spain
comorbidities
topic COVID-19
corticosteroids
Spain
comorbidities
description Objectives: Since the results of the RECOVERY trial, WHO recommendations about the use of corticosteroids (CTs) in COVID-19 have changed. The aim of the study is to analyse the evolutive use of CTs in Spain during the pandemic to assess the potential influence of new recommendations. Material and methods: A retrospective, descriptive, and observational study was conducted on adults hospitalised due to COVID-19 in Spain who were included in the SEMI-COVID-19 Registry from March to November 2020. Results: CTs were used in 6053 (36.21%) of the included patients. The patients were older (mean (SD)) (69.6 (14.6) vs. 66.0 (16.8) years; p < 0.001), with hypertension (57.0% vs. 47.7%; p < 0.001), obesity (26.4% vs. 19.3%; p < 0.0001), and multimorbidity prevalence (20.6% vs. 16.1%; p < 0.001). These patients had higher values (mean (95% CI)) of C-reactive protein (CRP) (86 (32.7-160) vs. 49.3 (16-109) mg/dL; p < 0.001), ferritin (791 (393-1534) vs. 470 (236-996) mu g/dL; p < 0.001), D dimer (750 (430-1400) vs. 617 (345-1180) mu g/dL; p < 0.001), and lower Sp0(2)/Fi0(2) (266 (91.1) vs. 301 (101); p < 0.001). Since June 2020, there was an increment in the use of CTs (March vs. September; p < 0.001). Overall, 20% did not receive steroids, and 40% received less than 200 mg accumulated prednisone equivalent dose (APED). Severe patients are treated with higher doses. The mortality benefit was observed in patients with oxygen saturation </=90%. Conclusions: Patients with greater comorbidity, severity, and inflammatory markers were those treated with CTs. In severe patients, there is a trend towards the use of higher doses. The mortality benefit was observed in patients with oxygen saturation </=90%.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/11503
url https://fisabio.portalinvestigacion.com/publicaciones/11503
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv Journal of Clinical Medicine
ISSN: 20770383
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869424862715445249
score 15.812429

Similares en LA Referencia